
Series C Round Summary (Overall Summary)
interpoint (interword separation)Cumulative amount raised in Series C: Approximately 1.9 billion yen
interpoint (interword separation)Underwriters:
Rohto Pharmaceutical Co.
S.R.D. Holdings Co.
CafeGroup Inc.
Nikko Chemicals Co.
Our Management
FUNDINNO PLUS + 125 specific investors
Other business companies and individual investors
Primary use of funds:
Preparation for Phase III Clinical Trial in Non-Infectious Pulmonary Complications (NIPCs) after Hematopoietic Stem Cell Transplantation
Strengthening of UC-MSCs master cell manufacturing system
Promote the establishment of a global manufacturing and supply system (ecosystem) for UC-MSCs
Mr. Masamitsu Harada, President and Representative Director Comments
We believe that your investment in UC-MSCs is not only a recognition of our vision and management, but also of the steady progress that UC-MSCs is making toward the "medical implementation of sustainable cell therapy". We are sincerely grateful for the entrustment of these important funds that will bring substantial value to society.
We are steadily building a framework for the start of Phase III clinical trials for noninfectious pulmonary complications after hematopoietic stem cell transplantation (NIPCs), the first in our pipeline. Based on this foundation, we will further accelerate the construction of a "global ecosystem of cell therapy" centered on Japan and the U.S., and deliver new options to patients around the world.
Human Life Code will continue to further strengthen its system from R&D to manufacturing and commercialization in order to deliver the potential of UC-MSCs to society as a reliable medical treatment.
In collaboration with our partners in Japan and abroad, we will continue our efforts to realize a future in which cell therapy is a more accessible and sustainable option.
About the Human Life Code
Human Life Cord Co., Ltd. manufactures and develops cell products from domestically produced and stockpileable umbilical cord (umbilical cord) ("cord"), and aims to connect them to the hope of life for patients with intractable diseases for which there is no established treatment today ("cord"). ), and beyond that, to future medical treatment aimed at preventing serious illnesses that will lead to an increase in healthy life expectancy ("code"), thereby creating a society in which everyone can realize a heart-enriching life ("human life "), our vision is to create a society in which everyone can lead a hearty life ("Human Life").
Received the Grand Prize and the Governor of Tokyo Award at the "1st Tokyo Venture Company Championship" in 2019. Selected as a company to be supported by "Deep Ecosystem" operated by "Startup Ecosystem Tokyo Consortium" sponsored by Tokyo Metropolitan Government. 2023 Awarded the Minister of Health, Labor and Welfare Prize at "5th Japan Open Innovation Awards" sponsored by the Cabinet Office. 2023 Selected as a company for "J-Startup", a startup support program by the Ministry of Economy, Trade and Industry. In 2024, the company won the grand prize in the startup category of the "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry.
| name of company | Human Life Code, Inc. |
| Establishment | Apr 2017 |
| Location | 75F Nihonbashi Life Science Building, 1-9-10 Nihonbashi Horidome-cho, Chuo-ku, Tokyo |
| representative | Masamitsu Harada |
| uniform resouce locator | http://www.humanlifecord.com/ |









